nach oben

Erschienen in:

29.08.2019 | Herzinsuffizienz | CME

Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz

verfasst von: Dr. med. L. Lauder, PD Dr. S. Ewen, Dr. I. E. Emrich, Prof. Dr. M. Böhm, Prof. Dr. F. Mahfoud

Erschienen in: Herz | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Herz und Nieren sind in ihrer physiologischen Interaktion eng miteinander verbunden. Kardiovaskuläre Erkrankungen sind die häufigste Todesursache bei Patienten mit chronischer Nierenerkrankung, wobei diese wiederum das Auftreten und das Fortschreiten kardiovaskulärer Erkrankungen begünstigen kann. Die Therapie der koronaren Herzkrankheit (KHK) und der chronischen Herzinsuffizienz unterscheidet sich bei Patienten mit einer milden Nierenfunktionseinschränkung (geschätzte glomeruläre Filtrationsrate [eGFR]: >60 ml/min/1,73 m²) nicht wesentlich von der Therapie nierengesunder Patienten. Da Patienten mit einer fortgeschrittenen Niereninsuffizienz aus den Zulassungsstudien meist ausgeschlossen wurden, basieren viele Therapieempfehlungen in dieser Patientengruppe auf Beobachtungsstudien, Subgruppen- und Metaanalysen oder pathophysiologischen Erwägungen, die nicht durch kontrollierte Studien gestützt sind. Daher werden prospektive, randomisierte Studien zur Therapie von KHK und Herzinsuffizienz benötigt, die Patienten mit fortgeschrittener Nierenfunktionseinschränkung gezielt untersuchen.

Marx N, Noels H, Jankowski J et al (2018) Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol 107:120–126. https://doi.org/10.1007/s00392-018-1260-0 CrossRefPubMed

Tonelli M, Muntner P, Lloyd A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:807–814. https://doi.org/10.1016/S0140-6736(12)60572-8 CrossRefPubMed

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:4. https://doi.org/10.1038/kisup.2012.76 CrossRef

Rangaswami J, Bhalla V, Blair JEA et al (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139:e840–e878. https://doi.org/10.1161/CIR.0000000000000664 CrossRefPubMed

Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. https://doi.org/10.1056/NEJMoa041031 CrossRefPubMed

Anavekar NS, McMurray JJV, Velazquez EJ et al (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285–1295. https://doi.org/10.1056/NEJMoa041365 CrossRefPubMed

Charytan D, Kuntz RE, Mauri L, DeFilippi C (2007) Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 49:409–416. https://doi.org/10.1053/j.ajkd.2006.11.042 CrossRefPubMed

Schmidt A, Stefenelli T, Schuster E, Mayer G (2001) Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 37:56–63. https://doi.org/10.1053/ajkd.2001.20584 CrossRefPubMed

Bangalore S (2016) Diagnostic, therapeutic, and clinical trial conundrum of patients with chronic kidney disease. JACC Cardiovasc Interv 9:2110–2112. https://doi.org/10.1016/j.jcin.2016.08.031 CrossRefPubMed

10.

Tebaldi M, Biscaglia S, Fineschi M et al (2016) Fractional flow reserve evaluation and chronic kidney disease: analysis from a multicenter Italian registry (the FREAK study). Catheter Cardiovasc Interv 88:555–562. https://doi.org/10.1002/ccd.26364 CrossRefPubMed

11.

Mehran R, Dangas GD, Weisbord SD (2019) Contrast-associated acute kidney injury. N Engl J Med 380:2146–2155. https://doi.org/10.1056/NEJMra1805256 CrossRefPubMed

12.

Ferrari R, Camici PG, Crea F et al (2018) A “diamond” approach to personalized treatment of angina. Nat Rev Cardiol 15:120–132. https://doi.org/10.1038/nrcardio.2017.131 CrossRefPubMed

13.

Montalescot G, Sechtem U, Achenbach S et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 34:2949–3003. https://doi.org/10.1093/eurheartj/eht296 CrossRefPubMed

14.

Belsey J, Savelieva I, Mugelli A, Camm AJ (2015) Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol 22(7):837–848. https://doi.org/10.1177/2047487314533217 CrossRefPubMed

15.

Jerling M (2006) Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 45:469–491. https://doi.org/10.2165/00003088-200645050-00003 CrossRefPubMed

16.

Borer JS, Fox K, Jaillon P, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in atable angina. Circulation 107:817–823. https://doi.org/10.1161/01.CIR.0000048143.25023.87 CrossRefPubMed

17.

Fox K, Ford I, Steg PG et al (2014) Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371:1091–1099. https://doi.org/10.1056/NEJMoa1406430 CrossRefPubMed

18.

Chaudhary R, Garg J, Krishnamoorthy P et al (2016) Ivabradine: heart failure and beyond. J Cardiovasc Pharmacol Ther 21:335–343. https://doi.org/10.1177/1074248415624157 CrossRefPubMed

19.

Palmer SC, Di Micco L, Razavian M et al (2012) Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. Ann Intern Med 156:445. https://doi.org/10.7326/0003-4819-156-6-201203200-00007 CrossRefPubMed

20.

Gargiulo G, Santucci A, Piccolo R et al (2017) Impact of chronic kidney disease on 2‑year clinical outcomes in patients treated with 6‑month or 24-month DAPT duration: an analysis from the PRODIGY trial. Catheter Cardiovasc Interv 90:E73–E84. https://doi.org/10.1002/ccd.26921 CrossRefPubMed

21.

Schuett K, Savvaidis A, Maxeiner S et al (2017) Clot structure: a potent mortality risk factor in patients on hemodialysis. J Am Soc Nephrol 28:1622–1630. https://doi.org/10.1681/ASN.2016030336 CrossRefPubMedPubMedCentral

22.

Tanios BY, Itani HS, Zimmerman DL (2015) Clopidogrel use in end-stage kidney disease. Semin Dial 28:276–281. https://doi.org/10.1111/sdi.12338 CrossRefPubMed

23.

Baber U, Chandrasekhar J, Sartori S et al (2017) Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 10:2017–2025. https://doi.org/10.1016/j.jcin.2017.02.047 CrossRefPubMed

24.

Bonello L, Angiolillo DJ, Aradi D, Sibbing D (2018) P2Y12 -ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes. Circulation 138:1582–1596. https://doi.org/10.1161/CIRCULATIONAHA.118.032078 CrossRefPubMed

25.

Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272 CrossRefPubMed

26.

Wanner C, Tonelli M (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309. https://doi.org/10.1038/ki.2014.31 CrossRefPubMed

27.

Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3 CrossRefPubMedPubMedCentral

28.

Tonelli M, Muntner P, Lloyd A et al (2014) Impact of age on the association between CKD and the risk of future coronary events. Am J Kidney Dis 64:375–382. https://doi.org/10.1053/j.ajkd.2014.03.013 CrossRefPubMed

29.

Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248. https://doi.org/10.1056/NEJMoa043545 CrossRefPubMed

30.

Fellström BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407. https://doi.org/10.1056/NEJMoa0810177 CrossRefPubMed

31.

Chonchol M, Whittle J, Desbien A et al (2008) Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 28:354–360. https://doi.org/10.1159/000111829 CrossRefPubMed

32.

Attallah N, Yassine L, Fisher K, Yee J (2005) Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 64:412–418. https://doi.org/10.5414/CNP64412 CrossRefPubMed

33.

Reddan DN, Szczech LA, Tuttle RH et al (2003) Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 14:2373–2380. https://doi.org/10.1097/01.ASN.0000083900.92829.F5 CrossRefPubMed

34.

Milojevic M, Head SJ, Mack MJ et al (2018) The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial. EuroIntervention 14:102–111. https://doi.org/10.4244/EIJ-D-17-00620 CrossRefPubMed

35.

Giustino G, Mehran R, Serruys PW et al (2018) Left main revascularization with PCI or CABG in patients with chronic kidney disease. J Am Coll Cardiol 72:754–765. https://doi.org/10.1016/j.jacc.2018.05.057 CrossRefPubMed

36.

Wang Y, Zhu S, Gao P, Zhang Q (2017) Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: a meta-analysis. Eur J Intern Med 43:28–35. https://doi.org/10.1016/j.ejim.2017.04.002 CrossRefPubMed

37.

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128 CrossRefPubMed

38.

Kottgen A, Russell SD, Loehr LR et al (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18:1307–1315. https://doi.org/10.1681/ASN.2006101159 CrossRefPubMed

39.

Foley RN (2003) The clinical epidemiology of cardiovascular diseases in chronic kidney disease: clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 16:111–117. https://doi.org/10.1046/j.1525-139X.2003.160271.x CrossRefPubMed

40.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J (2014) Physician visits and 30-day hospital readmissions in patients receiving hemodialysis. J Am Soc Nephrol 25:2079–2087. https://doi.org/10.1681/ASN.2013080879 CrossRefPubMedPubMedCentral

41.

Chen C, Yang X, Lei Y et al (2016) Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome. Clin J Am Soc Nephrol 11:1536–1544. https://doi.org/10.2215/CJN.00910116 CrossRefPubMedPubMedCentral

42.

Jackson CE, MacDonald MR, Petrie MC et al (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. Eur J Heart Fail 13:746–754. https://doi.org/10.1093/eurjhf/hfr031 CrossRefPubMed

43.

Katz DH, Burns JA, Aguilar FG et al (2014) Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 2:586–596. https://doi.org/10.1016/j.jchf.2014.05.016 CrossRefPubMedPubMedCentral

44.

Velazquez EJ, Morrow DA, DeVore AD et al (2019) Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380:539–548. https://doi.org/10.1056/NEJMoa1812851 CrossRefPubMed

45.

Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1531 CrossRefPubMed

46.

Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013) Rehospitalization for heart failure. J Am Coll Cardiol 61:391–403. https://doi.org/10.1016/j.jacc.2012.09.038 CrossRefPubMed

47.

Ferreira JP, Santos M, Almeida S et al (2013) Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 102:745–753. https://doi.org/10.1007/s00392-013-0588-8 CrossRefPubMed

48.

Faris R, Flather M, Purcell H et al (2001) Diuretics for heart failure. In: Faris R (Hrsg) Cochrane database of systematic reviews. John Wiley & Sons, Chichester

49.

Faris R, Flather M, Purcell H et al (2002) Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 82:149–158. https://doi.org/10.1016/S0167-5273(01)00600-3 CrossRefPubMed

50.

Ellison DH, Felker GM (2017) Diuretic treatment in heart failure. N Engl J Med 377:1964–1975. https://doi.org/10.1056/NEJMra1703100 CrossRefPubMedPubMedCentral

51.

Damman K, Valente MAE, Voors AA et al (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469. https://doi.org/10.1093/eurheartj/eht386 CrossRefPubMed

52.

Testani JM, Chen J, McCauley BD et al (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:265–272. https://doi.org/10.1161/CIRCULATIONAHA.109.933275 CrossRefPubMedPubMedCentral

53.

Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296–2304. https://doi.org/10.1056/NEJMoa1210357 CrossRefPubMedPubMedCentral

54.

Frea S, Pidello S, Volpe A et al (2019) Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure—bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01521-y CrossRefPubMed

55.

MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007. https://doi.org/10.1016/S0140-6736(99)04440-2 CrossRef

56.

Dargie HJ, Lechat P (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13. https://doi.org/10.1016/S0140-6736(98)11181-9 CrossRef

57.

Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355. https://doi.org/10.1056/NEJM199605233342101 CrossRefPubMed

58.

Flather MD, Shibata MC, Coats AJS et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225. https://doi.org/10.1093/eurheartj/ehi115 CrossRefPubMed

59.

House AA, Wanner C, Sarnak MJ et al (2019) Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95:1304–1317. https://doi.org/10.1016/j.kint.2019.02.022 CrossRefPubMed

60.

Ghali JK, Wikstrand J, Van Veldhuisen DJ et al (2009) The influence of renal function on clinical outcome and response to β‑blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 15:310–318. https://doi.org/10.1016/j.cardfail.2008.11.003 CrossRefPubMed

61.

Badve SV, Roberts MA, Hawley CM et al (2011) Effects of beta-adrenergic antagonists in patients with chronic kidney disease. J Am Coll Cardiol 58:1152–1161. https://doi.org/10.1016/j.jacc.2011.04.041 CrossRefPubMed

62.

McDevitt DG (1987) Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J 8:9–14. https://doi.org/10.1093/eurheartj/8.suppl_M.9 CrossRefPubMed

63.

Cice G, Ferrara L, D’Andrea A et al (2003) Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 41:1438–1444. https://doi.org/10.1016/S0735-1097(03)00241-9 CrossRefPubMed

64.

Weir MA, Dixon SN, Fleet JL et al (2015) β‑blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 26:987–996. https://doi.org/10.1681/ASN.2014040324 CrossRefPubMed

65.

Bowling CB, Sanders PW, Allman RM et al (2013) Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. Int J Cardiol 167:151–156. https://doi.org/10.1016/j.ijcard.2011.12.056 CrossRefPubMed

66.

Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 70:479–487. https://doi.org/10.1016/0002-9149(92)91194-9 CrossRefPubMed

67.

Edner M, Benson L, Dahlström U, Lund LH (2015) Association between renin–angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J 36:2318–2326. https://doi.org/10.1093/eurheartj/ehv268 CrossRefPubMed

68.

McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRefPubMed

69.

Damman K, Gori M, Claggett B et al (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6:489–498. https://doi.org/10.1016/j.jchf.2018.02.004 CrossRefPubMed

70.

Haynes R, Judge PK, Staplin N et al (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138:1505–1514. https://doi.org/10.1161/CIRCULATIONAHA.118.034818 CrossRefPubMed

71.

Athyros VG, Mikhailidis DP, Kakafika AI et al (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8:529–535. https://doi.org/10.1517/14656566.8.5.529 CrossRefPubMed

72.

van der Horst ICC, Voors AA, van Veldhuisen DJ (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clin Res Cardiol 96:193–195. https://doi.org/10.1007/s00392-007-0487-y CrossRefPubMedPubMedCentral

73.

Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717. https://doi.org/10.1056/NEJM199909023411001 CrossRefPubMed

74.

Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21. https://doi.org/10.1056/NEJMoa1009492 CrossRefPubMed

75.

Matsumoto Y, Mori Y, Kageyama S et al (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63:528–536. https://doi.org/10.1016/j.jacc.2013.09.056 CrossRefPubMed

76.

Hammer F, Malzahn U, Donhauser J et al (2019) A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 95:983–991. https://doi.org/10.1016/j.kint.2018.11.025 CrossRefPubMed

77.

Charytan DM, Himmelfarb J, Ikizler TA et al (2019) Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 95:973–982. https://doi.org/10.1016/j.kint.2018.08.034 CrossRefPubMed

78.

Pitt B, Ferreira PJ, Zannad F (2017) Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 3:48–57. https://doi.org/10.1093/ehjcvp/pvw016 CrossRefPubMed

79.

Fox K, Ford I, Steg PG et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816. https://doi.org/10.1016/S0140-6736(08)61170-8 CrossRefPubMed

80.

Fox K, Ford I, Steg PG et al (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821. https://doi.org/10.1016/S0140-6736(08)61171-X CrossRefPubMed

81.

Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885. https://doi.org/10.1016/S0140-6736(10)61198-1 CrossRefPubMed

82.

Voors AA, van Veldhuisen DJ, Robertson M et al (2014) The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail 16:426–434. https://doi.org/10.1002/ejhf.59 CrossRefPubMed

83.

Ouwerkerk W, Voors AA, Anker SD et al (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38:1883–1890. https://doi.org/10.1093/eurheartj/ehx026 CrossRefPubMed

84.

Maggioni AP, Anker SD, Dahlström U et al (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:1173–1184. https://doi.org/10.1093/eurjhf/hft134 CrossRefPubMed

85.

Pitt B, Anker SD, Bushinsky DA et al (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32:820–828. https://doi.org/10.1093/eurheartj/ehq502 CrossRefPubMedPubMedCentral

86.

Anker SD, Kosiborod M, Zannad F et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17:1050–1056. https://doi.org/10.1002/ejhf.300 CrossRefPubMed

87.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

88.

Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney cisease. Circulation 137:119–129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268 CrossRefPubMed

89.

Inzucchi SE, Kosiborod M, Fitchett D et al (2018) Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 138:1904–1907. https://doi.org/10.1161/CIRCULATIONAHA.118.035759 CrossRefPubMed

90.

Rådholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138:458–468. https://doi.org/10.1161/CIRCULATIONAHA.118.034222 CrossRefPubMedPubMedCentral

91.

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389 CrossRefPubMed

92.

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X CrossRefPubMed

93.

Wanner C, Heerspink HJL, Zinman B et al (2018) Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. https://doi.org/10.1681/ASN.2018010103 CrossRefPubMedPubMedCentral

94.

Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744 CrossRefPubMed

95.

Ghosh RK, Bandyopadhyay D, Hajra A et al (2016) Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol 212:29–36. https://doi.org/10.1016/j.ijcard.2016.02.134 CrossRefPubMed

Titel: Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz
verfasst von: Dr. med. L. Lauder
PD Dr. S. Ewen
Dr. I. E. Emrich
Prof. Dr. M. Böhm
Prof. Dr. F. Mahfoud
Publikationsdatum: 29.08.2019
Verlag: Springer Medizin
Schlagwörter: Herzinsuffizienz
Störungen der Nierenfunktion in der Intensivmedizin
Koronare Herzerkrankung
Erschienen in: Herz / Ausgabe 7/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04846-6

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Interventionelle Therapie der Mitralklappe – ein Update

Left ventricular hypertrabeculation/noncompaction, cardiac phenotype, and neuromuscular disorders

In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization

Diagnostik der Mitralinsuffizienz

Effect of levosimendan in patients with acute decompensated heart failure

Influence of riociguat treatment on pulmonary arterial hypertension